- Home
- NTIP vs RVPH Comparison
NTIP vs RVPH Comparison
Compare NTIP & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- RVPH
- Stock Information
- Founded
- NTIP 1990
- RVPH 2006
- Country
- NTIP United States
- RVPH United States
- Employees
- NTIP N/A
- RVPH N/A
- Industry
- NTIP Multi-Sector Companies
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- RVPH Health Care
- Exchange
- NTIP Nasdaq
- RVPH Nasdaq
- Market Cap
- NTIP 29.5M
- RVPH 33.4M
- IPO Year
- NTIP 1998
- RVPH N/A
- Fundamental
- Price
- NTIP $1.33
- RVPH $1.13
- Analyst Decision
- NTIP
- RVPH Strong Buy
- Analyst Count
- NTIP 0
- RVPH 4
- Target Price
- NTIP N/A
- RVPH $15.33
- AVG Volume (30 Days)
- NTIP 49.6K
- RVPH 697.8K
- Earning Date
- NTIP 10-24-2024
- RVPH 11-26-2024
- Dividend Yield
- NTIP 7.41%
- RVPH N/A
- EPS Growth
- NTIP N/A
- RVPH N/A
- EPS
- NTIP N/A
- RVPH N/A
- Revenue
- NTIP $1,881,000.00
- RVPH N/A
- Revenue This Year
- NTIP N/A
- RVPH N/A
- Revenue Next Year
- NTIP N/A
- RVPH N/A
- P/E Ratio
- NTIP N/A
- RVPH N/A
- Revenue Growth
- NTIP 129.39
- RVPH N/A
- 52 Week Low
- NTIP $1.24
- RVPH $0.60
- 52 Week High
- NTIP $2.25
- RVPH $5.67
- Technical
- Relative Strength Index (RSI)
- NTIP 50.04
- RVPH 49.00
- Support Level
- NTIP $1.29
- RVPH $0.88
- Resistance Level
- NTIP $1.34
- RVPH $1.45
- Average True Range (ATR)
- NTIP 0.04
- RVPH 0.14
- MACD
- NTIP 0.01
- RVPH 0.02
- Stochastic Oscillator
- NTIP 76.56
- RVPH 42.98
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.